

# Commercializing Biomarkers-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/C32D5B8B566MEN.html>

Date: March 2018

Pages: 139

Price: US\$ 3,480.00 (Single User License)

ID: C32D5B8B566MEN

## Abstracts

### Report Summary

Commercializing Biomarkers-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Commercializing Biomarkers industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Commercializing Biomarkers 2013-2017, and development forecast 2018-2023

Main market players of Commercializing Biomarkers in Europe, with company and product introduction, position in the Commercializing Biomarkers market

Market status and development trend of Commercializing Biomarkers by types and applications

Cost and profit status of Commercializing Biomarkers, and marketing status

Market growth drivers and challenges

The report segments the Europe Commercializing Biomarkers market as:

Europe Commercializing Biomarkers Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Commercializing Biomarkers Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Consumables

Services

Software

Europe Commercializing Biomarkers Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and  
Market Analysis)

Oncology

Cardiology

Neurology

Others

Europe Commercializing Biomarkers Market: Players Segment Analysis (Company and  
Product introduction, Commercializing Biomarkers Sales Volume, Revenue, Price and  
Gross Margin):

Roche

Dako (Agilent Technologies)

Merck

BD

Abbott

Genesys Biolabs (20/20GeneSystems)

Affymetrix

Agendia

ALMAC

Arrayit

Biocartic

BG Medicine

KEGG EXPRESSION Database

Thermo Fisher

BGI

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF COMMERCIALIZING BIOMARKERS**

- 1.1 Definition of Commercializing Biomarkers in This Report
- 1.2 Commercial Types of Commercializing Biomarkers
  - 1.2.1 Consumables
  - 1.2.2 Services
  - 1.2.3 Software
- 1.3 Downstream Application of Commercializing Biomarkers
  - 1.3.1 Oncology
  - 1.3.2 Cardiology
  - 1.3.3 Neurology
  - 1.3.4 Others
- 1.4 Development History of Commercializing Biomarkers
- 1.5 Market Status and Trend of Commercializing Biomarkers 2013-2023
  - 1.5.1 Europe Commercializing Biomarkers Market Status and Trend 2013-2023
  - 1.5.2 Regional Commercializing Biomarkers Market Status and Trend 2013-2023

### **CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Commercializing Biomarkers in Europe 2013-2017
- 2.2 Consumption Market of Commercializing Biomarkers in Europe by Regions
  - 2.2.1 Consumption Volume of Commercializing Biomarkers in Europe by Regions
  - 2.2.2 Revenue of Commercializing Biomarkers in Europe by Regions
- 2.3 Market Analysis of Commercializing Biomarkers in Europe by Regions
  - 2.3.1 Market Analysis of Commercializing Biomarkers in Germany 2013-2017
  - 2.3.2 Market Analysis of Commercializing Biomarkers in United Kingdom 2013-2017
  - 2.3.3 Market Analysis of Commercializing Biomarkers in France 2013-2017
  - 2.3.4 Market Analysis of Commercializing Biomarkers in Italy 2013-2017
  - 2.3.5 Market Analysis of Commercializing Biomarkers in Spain 2013-2017
  - 2.3.6 Market Analysis of Commercializing Biomarkers in Benelux 2013-2017
  - 2.3.7 Market Analysis of Commercializing Biomarkers in Russia 2013-2017
- 2.4 Market Development Forecast of Commercializing Biomarkers in Europe 2018-2023
  - 2.4.1 Market Development Forecast of Commercializing Biomarkers in Europe 2018-2023
  - 2.4.2 Market Development Forecast of Commercializing Biomarkers by Regions 2018-2023

## **CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of Commercializing Biomarkers in Europe by Types

3.1.2 Revenue of Commercializing Biomarkers in Europe by Types

### 3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

### 3.3 Market Forecast of Commercializing Biomarkers in Europe by Types

## **CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

### 4.1 Demand Volume of Commercializing Biomarkers in Europe by Downstream Industry

### 4.2 Demand Volume of Commercializing Biomarkers by Downstream Industry in Major Countries

4.2.1 Demand Volume of Commercializing Biomarkers by Downstream Industry in Germany

4.2.2 Demand Volume of Commercializing Biomarkers by Downstream Industry in United Kingdom

4.2.3 Demand Volume of Commercializing Biomarkers by Downstream Industry in France

4.2.4 Demand Volume of Commercializing Biomarkers by Downstream Industry in Italy

4.2.5 Demand Volume of Commercializing Biomarkers by Downstream Industry in Spain

4.2.6 Demand Volume of Commercializing Biomarkers by Downstream Industry in Benelux

4.2.7 Demand Volume of Commercializing Biomarkers by Downstream Industry in Russia

### 4.3 Market Forecast of Commercializing Biomarkers in Europe by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF COMMERCIALIZING BIOMARKERS**

5.1 Europe Economy Situation and Trend Overview

5.2 Commercializing Biomarkers Downstream Industry Situation and Trend Overview

## **CHAPTER 6 COMMERCIALIZING BIOMARKERS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE**

6.1 Sales Volume of Commercializing Biomarkers in Europe by Major Players

6.2 Revenue of Commercializing Biomarkers in Europe by Major Players

6.3 Basic Information of Commercializing Biomarkers by Major Players

6.3.1 Headquarters Location and Established Time of Commercializing Biomarkers Major Players

6.3.2 Employees and Revenue Level of Commercializing Biomarkers Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 COMMERCIALIZING BIOMARKERS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Roche

7.1.1 Company profile

7.1.2 Representative Commercializing Biomarkers Product

7.1.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Roche

7.2 Dako (Agilent Technologies)

7.2.1 Company profile

7.2.2 Representative Commercializing Biomarkers Product

7.2.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Dako (Agilent Technologies)

7.3 Merck

7.3.1 Company profile

7.3.2 Representative Commercializing Biomarkers Product

7.3.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Merck

7.4 BD

7.4.1 Company profile

7.4.2 Representative Commercializing Biomarkers Product

7.4.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of BD

7.5 Abbott

7.5.1 Company profile

- 7.5.2 Representative Commercializing Biomarkers Product
- 7.5.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Abbott
- 7.6 Genesys Biolabs (20/20GeneSystems)
  - 7.6.1 Company profile
  - 7.6.2 Representative Commercializing Biomarkers Product
  - 7.6.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Genesys Biolabs (20/20GeneSystems)
- 7.7 Affymetrix
  - 7.7.1 Company profile
  - 7.7.2 Representative Commercializing Biomarkers Product
  - 7.7.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Affymetrix
- 7.8 Agendia
  - 7.8.1 Company profile
  - 7.8.2 Representative Commercializing Biomarkers Product
  - 7.8.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Agendia
- 7.9 ALMAC
  - 7.9.1 Company profile
  - 7.9.2 Representative Commercializing Biomarkers Product
  - 7.9.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of ALMAC
- 7.10 Arrayit
  - 7.10.1 Company profile
  - 7.10.2 Representative Commercializing Biomarkers Product
  - 7.10.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Arrayit
- 7.11 Biocartic
  - 7.11.1 Company profile
  - 7.11.2 Representative Commercializing Biomarkers Product
  - 7.11.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Biocartic
- 7.12 BG Medicine
  - 7.12.1 Company profile
  - 7.12.2 Representative Commercializing Biomarkers Product
  - 7.12.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of BG Medicine
- 7.13 KEGG EXPRESSION Database
  - 7.13.1 Company profile

- 7.13.2 Representative Commercializing Biomarkers Product
- 7.13.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of KEGG EXPRESSION Database
- 7.14 Thermo Fisher
  - 7.14.1 Company profile
  - 7.14.2 Representative Commercializing Biomarkers Product
  - 7.14.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of Thermo Fisher
- 7.15 BGI
  - 7.15.1 Company profile
  - 7.15.2 Representative Commercializing Biomarkers Product
  - 7.15.3 Commercializing Biomarkers Sales, Revenue, Price and Gross Margin of BGI

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF COMMERCIALIZING BIOMARKERS**

- 8.1 Industry Chain of Commercializing Biomarkers
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF COMMERCIALIZING BIOMARKERS**

- 9.1 Cost Structure Analysis of Commercializing Biomarkers
- 9.2 Raw Materials Cost Analysis of Commercializing Biomarkers
- 9.3 Labor Cost Analysis of Commercializing Biomarkers
- 9.4 Manufacturing Expenses Analysis of Commercializing Biomarkers

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF COMMERCIALIZING BIOMARKERS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference



## I would like to order

Product name: Commercializing Biomarkers-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/C32D5B8B566MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C32D5B8B566MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970